Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ORKA | CLUSTER | neutral | 2/10 | Two insiders at Oruka Therapeutics, General Counsel Paul Quinlan and Director Carl Dambkowski, sold a combined $933K in | Jun 15, 2026 |
| ATRA | 3 | neutral | 2/10 | Brian N. Cherry filed a Form 3 initial statement of beneficial ownership, reporting 38,320 shares of Atara Biotherapeuti | Jun 15, 2026 |
| ANIP | CLUSTER | neutral | 2/10 | Three ANIP insiders (Director, CFO, and General Counsel) sold a total of $468K in open-market transactions over a 7-day | Jun 15, 2026 |
| LYEL | CLUSTER | neutral | 2/10 | Lyell Immunopharma insiders executed negligible open-market sales totaling $8K (0.003% of market cap) in early May 2026, | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Director and Officer Mark A. Goldsmith filed a Form 144 indicating intent to sell 9,772 shares of Revolution Medicines c | Jun 15, 2026 |
| NATR | CLUSTER | neutral | 2/10 | Two EVP/Presidents at Nature's Sunshine Products sold a combined $262K in open-market transactions over a 7-day window. | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Officer Stephen Michael Kelsey filed a Form 144 notice of intent to sell 4,071 shares of Revolution Medicines common sto | Jun 15, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Five BeOne Medicines insiders, including the CEO, sold a total of $1.98M in open-market shares over a one-week window. T | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Officer Margaret A. Horn filed a Form 144 notice of intent to sell 3,486 shares of Revolution Medicines common stock, va | Jun 15, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Five insiders at BeOne Medicines (ONC) sold a total of $2.0M in shares on June 8, 2026, led by CEO John Oyler ($1.03M). | Jun 15, 2026 |
| ANAB | 144 | bearish | 6/10 | CEO Dennis Mulroy filed a Form 144 notice of intent to sell 20,000 shares of ANAB common stock, valued at approximately | Jun 15, 2026 |
| BFRG | 8-K | neutral | 2/10 | BullFrog AI Holdings filed an 8-K reporting a CEO salary increase from $400,000 to $600,000 and the results of its 2026 | Jun 15, 2026 |
| NNVC | S-3 | neutral | 3/10 | NanoViricides filed an S-3 registration statement to register 1,333,334 shares of common stock for resale by selling sto | Jun 15, 2026 |
| CVM | 424B5 | bearish | 6/10 | CEL-SCI is offering 2,500,000 shares at $1.00 per share in a best-efforts offering with no minimum, targeting $2.5M gros | Jun 15, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation has been made available on its webs | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Margaret A. Horn, an officer at Revolution Medicines, filed a Form 144 to sell 90,000 common shares (~$13.85M at filing | Jun 15, 2026 |
| TARS | 144 | neutral | 2/10 | Director William J. Link filed a Form 144 notice of intent to sell 12,500 shares of Tarsus Pharmaceuticals common stock, | Jun 15, 2026 |
| PHVS | 144 | neutral | 2/10 | Director and Officer Berndt Modig filed a Form 144 to sell 2,291 shares of Pharvaris N.V. common stock, valued at approx | Jun 15, 2026 |
| ARDX | 144 | neutral | 3/10 | Director Michael Raab filed a Form 144 notice of intent to sell 125,000 shares of Ardelyx common stock, with an approxim | Jun 15, 2026 |
| WLK | 8-K | neutral | 4/10 | Westlake completed the previously-announced acquisition of a PVC and VCM production site in Wilhelmshaven, Germany, whic | Jun 15, 2026 |
| NTHI | S-3 | bearish | 5/10 | NeOnc Technologies filed an S-3 registration statement to register 555,554 shares of common stock for resale by selling | Jun 15, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Two CYTK insiders, including the CEO and EVP of R&D, sold a combined $766K in open-market transactions over a week. The | Jun 15, 2026 |
| CHRS | 8-K | neutral | 3/10 | Coherus Oncology dismissed Ernst & Young as its independent auditor and appointed PricewaterhouseCoopers, effective June | Jun 15, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Five BeOne Medicines insiders, including the CEO, sold a total of $2.0M in shares on June 8, 2026. This represents only | Jun 15, 2026 |
| PURE | 8-K | neutral | 4/10 | PURE Bioscience reported fiscal Q3 2026 revenue of $506,000 (+3% YoY) but net loss widened to $624,000 from $580,000 a y | Jun 15, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | UTHR CEO and CFO sold shares totaling $239K in open-market transactions over a two-day window, alongside routine option | Jun 15, 2026 |
| IMVT | 144 | neutral | 2/10 | Director Atul Pande intends to sell 6,000 shares of Immunovant common stock, valued at approximately $201,720, via a Rul | Jun 15, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen reported fiscal year 2026 financial results with net loss widening to $69.7M and cash at $45.4M, while providin | Jun 15, 2026 |
| VTRS | 8-K | neutral | 3/10 | Viatris entered into an underwriting agreement to issue €650M of 4.250% Senior Notes due 2033, a routine debt capital ma | Jun 15, 2026 |
| INBX | 8-K | bullish | 7/10 | Inhibrx announced FDA acceptance of its BLA for ozekibart (INBRX-109) in unresectable or metastatic conventional chondro | Jun 15, 2026 |